Abstracts Archive - Page 2473 of 2605 - ACR Meeting Abstracts

Abstract Number: 1956 • 2012 ACR/ARHP Annual Meeting
A New Linked Set of Autoantibodies in Dermatomyositis: Anti-Mi-2 and Anti-Transcription Intermediary Factor (TIF) 1alpha
Minoru Satoh¹, Jason YF Chan¹, Yi Li¹, Monica Vázquez-Del Mercado², Marcelo Petri³, Luis J. Jara⁴, Miguel A. Saavedra⁵, Claudia Cruz-Reyes⁶, Eric S. Sobel⁷, Westley H. Reeves⁸, Angela Ceribelli⁹ and Edward K.L. Chan⁹, ¹Medicine, University of Florida, Gainesville, FL, ²Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Hospital Civil JIM, Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico, ³Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁴Research and Education, Hospital de Especialidades Centro Medico La Raza, México City, Mexico, ⁵Centro Medico La Raza Instituto Mexicano del Seguro Social Mexico D.F., México D.F., Mexico, ⁶Centro Medico La Raza Instituto Mexicano del Seguro Social Mexico D.F., Mexico D. F., Mexico, ⁷Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁸Rheumatology & Clinical Imm, University of Florida, Gainesville, FL, ⁹Oral Biology, University of Florida, Gainesville, FL
Background/Purpose: Myositis specific autoantibodies (MSA) produced in patients with polymyositis/dermatomyositis (PM/DM) are clinically useful biomarkers in diagnosis and management. Anti-Mi-2 antibodies that recognize nucleosome remodeling…
Abstract Number: 1957 • 2012 ACR/ARHP Annual Meeting
Prevalence and Associated Factors of Vitamin D Insufficiency and Deficiency in 4,793 Japanese Patients with Rheumatoid Arthritis
Takefumi Furuya¹, Takayuki Hosoi², Eiichi Tanaka³, Ayako Nakajima⁴, Atsuo Taniguchi⁵, Shigeki Momohara¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Clinical Research and Development, National Center for Geriatrics and Gerontology, Aichi, Japan, ³Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁵Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Vitamin D (25[OH]D) insufficiency and deficiency is reported to be common in patients with rheumatoid arthritis (RA) and is associated with increased disease activity…
Abstract Number: 1958 • 2012 ACR/ARHP Annual Meeting
Bone Mineral Density in Lupus Erythematosus Women One Year After Rituximab Therapy
Claudia Mendoza-Pinto¹, Mario Garcia-Carrasco¹, Mario Jiménez-Hernández¹, Alma Rodríguez-Gallegos², Socorro Méndez-Martínez¹ and Aurelio Lopez-Colombo³, ¹Systemic Autoimmune Disease, HGR 36 CMN Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Laboratorios Clínicos de Puebla, Puebla, Mexico, ³Research Departament, Delegación Estatal, Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: Low bone mineral density (BMD) and osteoporosis may be significant complications in patients with systemic lupus erythematosus (SLE). Recent studies have shown that biologic therapy could…
Abstract Number: 1919 • 2012 ACR/ARHP Annual Meeting
Regulatory T Cells in IgG4-Related Disease Patients Presenting with Sclerosing Sialadenitis and Dacryoadenitis
Winnie K. Pang¹, Ya Liu², Julie Wang², Song Guo Zheng², Kiran Qidwai³, Russell K. Brynes³ and Francisco P. Quismorio Jr.¹, ¹Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: IgG4-Related Disease (IgG4-RD) is characterized by inflammation and fibrosis of various organ systems. Its diverse clinical presentations include autoimmune pancreatitis, retroperitoneal fibrosis, sialadenitis, and…
Abstract Number: 1920 • 2012 ACR/ARHP Annual Meeting
Spectrum of IgG4-Related Disease and Diagnostic Value of Serum IgG4 Determinations
Emma Kotisalmi¹, Tom Pettersson², Aaro Miettinen³, Johanna Arola⁴ and Martti Färkkilä⁵, ¹Department of Medicine, University of Helsinki, Helsinki, Finland, ²Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland, ³Department of Immunology, Huslab, Helsinki, Finland, ⁴Department of Pathology, University of Helsinki and Huslab, Helsinki, Finland, ⁵Department of Gastroenterology, Helsinki University Central Hospital, Helsinki, Finland
Background/Purpose: IgG4-related disease is a recently described systemic inflammatory and fibrosing condition that may mimic various other systemic rheumatic diseases. We studied the occurrence of…
Abstract Number: 1921 • 2012 ACR/ARHP Annual Meeting
Diagnostic Utility of Serum IgG4 in IgG4-Related Disease
Mollie Carruthers¹, Tamara Augustin², John H. Stone¹ and Arezou Khosroshahi¹, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Internal Medicine, Internal Medicine, Northshore Medical Center, Salem, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a recently recognized fibro-inflammatory disease with multi-organ system involvement, often but not always characterized by elevated serum IgG4 concentrations. The…
Abstract Number: 1922 • 2012 ACR/ARHP Annual Meeting
Articular Involvement in Relapsing Polychondritis: A Case Series
Laura O. Damian¹, Linda Ghib², Ioana Felea¹, Alma Maniu³, Nadia Radics², Simona Falaus², Ileana Filipescu⁴, Siao-pin Simon⁵ and Simona Rednic⁶, ¹Rheumatology, Emergency Clinical County Hospital Cluj, Cluj-Napoca, Romania, ²Rheumatology, Emergency County Clinical Hospital Cluj Napoca, Cluj Napoca, Romania, ³Otorhynolaringology, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj Napoca, Cluj Napoca, Romania, ⁴Rheumatology, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj Napoca, Cluj-Napoca, Romania, ⁵Rheumatology, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj Napoca, Cluj Napoca, Romania, ⁶Clinical County Emergency Hospital, Cluj-Napoca, Romania
Background/Purpose: Relapsing polychondritis (RP) is a relatively rare, but progressive disease with predilection for cartilage, with few data available regarding the arthritis in this setting.…
Abstract Number: 1923 • 2012 ACR/ARHP Annual Meeting
Biologics in Relapsing Polychondritis: A Single Center Case-Series
Guillaume Moulis¹, Laurent Sailler², Grégory Pugnet³, Leonardo Astudillo² and Philippe Arlet¹, ¹Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, Toulouse, France, ²Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, ³Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France
Background/Purpose: First-line treatment for relapsing polychondritis (RP) is costicosteroids (CS). Dapsone and methotrexate have been proposed as second-line therapies. Only few reports have been published…
Abstract Number: 1924 • 2012 ACR/ARHP Annual Meeting
What Do Patients with Polmyalgia Rheumatica Mean When They Describe Stiffness? A Qualitative Study
Rodney A. Hughes¹, Sarah Mackie², John R. Kirwan³, Colin T. Pease⁴, Margaret Walsh¹ and Marianne Morris⁵, ¹Rheumatology, St. Peters Hospital, Chertsey Surrey, United Kingdom, ²Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ³Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ⁴Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵University of the West of England, Bristol, United Kingdom
Background/Purpose: Patients with PMR report significant symptoms of pain and stiffness. Stiffness has usually been included in diagnostic criteria for PMR but has never been…
Abstract Number: 1925 • 2012 ACR/ARHP Annual Meeting
Patient Satisfaction and Experience with Golimumab, Adalimumab, and Etanercept for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Susan Bolge¹, Helen Eldridge², Dilesh Doshi¹, Lorie Ellis³, Barbara Roland⁴ and John Woelfel⁴, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Janssen Services, LLC., Titusville, NJ, ³Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, ⁴The Dominion Group, Reston, VA
Title: Patient Satisfaction and Experience with Golimumab, Adalimumab, and Etanercept for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Background/Purpose: Golimumab (GLM), adalimumab…
Abstract Number: 1926 • 2012 ACR/ARHP Annual Meeting
Evaluation of Strategies to Taper Anti-TNF Drugs in Patients with Inflammatory Rheumatic Disease (Rheumatoid Arthritis, Ankyloing Spondylitis, Psoriatic Arthritis, Adult-age Juvenile Idiopatic Arthritis) in Long-Term Remission
Jakub Zavada¹, Katarina Hviscova², Katerina Jarosova², Sarka Forejtova³, Jiri Stolfa², Liliana Sedova², Dana Tegzova², Jiri Vencovsky² and Karel Pavelka², ¹Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Prague, Czech Republic
Background/Purpose: While abrupt discontinuation strategies of anti-TNF drugs have been shown to result in frequent disease flares, tapering of dose may be a feasible…
Abstract Number: 1927 • 2012 ACR/ARHP Annual Meeting
Inflammatory Meningeal Involvement in Patients with Rheumatic Diseases Responsive to Rituximab
Jane Park¹, Eyal Kedar¹, Ingeborg Sacksen¹, John Henson² and Gregory C. Gardner³, ¹Rheumatology, University of Washington, Seattle, WA, ²Neurology, Swedish Neuroscience Institute, Seattle, WA, ³Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Inflammatory meningeal involvement can be idiopathic or associated with a variety of inflammatory rheumatic diseases such as ANCA associated vasculitis (AAV), rheumatoid (RA) arthritis,…
Abstract Number: 1928 • 2012 ACR/ARHP Annual Meeting
Evaluating the Therapeutic Effects of B Cell Depletion Therapy with Rituximab in a Longitudinal Cohort of Mixed Connective Tissue Disease Patients
Ragnar Gunnarsson¹, Inge-Margrethe Gilboe¹, Torhild Garen² and Øyvind Molberg³, ¹Rheumatology unit, Oslo University Hospital Rikshospitalet, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway
Background/Purpose: Even though 40 years have passed since MCTD was defined as a distinct disorder, there is still no evidence based therapy available. The choice…
Abstract Number: 1929 • 2012 ACR/ARHP Annual Meeting
Pernicious Anemia and Vitamin B-12 Deficiency in Autoimmune Disease: Neglecting the Feet Will Lead You Astray
Michael R. Lovy, Desert Oasis Healthcare, Palm Springs, CA
Background/Purpose: The occurrence of multiple autoimmune disorders in individual patients is commonly observed. Rarely, this is explained by recently recognized genetically based autoimmune polyendocrine syndromes.…
Abstract Number: 1930 • 2012 ACR/ARHP Annual Meeting
Progranulin Plays a Protective Role in the Pathogenesis of Inflammatory Bowel Disease
Fanhua Wei¹, Jinlong Jian¹, Yuying Zhang¹, Jiqiang Lin¹, Juan Lafaille², Michael Dustin³, Lloyd Mayer⁴ and Chuanju Liu¹, ¹Orthopaedic Surgery, NYU Hospital for Joint Diseases, New York, NY, ²New York University School of Medicine, New York, NY, ³Skirball Inst Fl 2 Labs 4 & 5, NYU School of Medicine, New York, NY, ⁴Div of Clinical Immunology, Mount Sinai Medical Center, New York, NY
Background/Purpose: Progranulin (PGRN) is a growth factor with multiple functions. We recently reported that PGRN and its derived engineered protein Atsttrin directly bound to TNF…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].